Cargando…
Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head
BACKGROUD: Outcomes of traditional treatment for osteonecrosis of the femoral head (ONFH) are not always satisfactory. Hence, cell-supplementation therapy has been attempted to facilitate necrotic-tissue regeneration. Adipose-derived mesenchymal stem cell (ADMSC) transplantation is potentially advan...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Orthopaedic Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948035/ https://www.ncbi.nlm.nih.gov/pubmed/33747376 http://dx.doi.org/10.4055/cios20128 |
_version_ | 1783663348742619136 |
---|---|
author | Yoon, Pil Whan Kang, Jong Yeal Kim, Chul-Ho Lee, Soong Joon Yoo, Jeong Joon Kim, Hee Joong Kang, Sung Keun Min, Ju Hyeon Yoon, Kang Sup |
author_facet | Yoon, Pil Whan Kang, Jong Yeal Kim, Chul-Ho Lee, Soong Joon Yoo, Jeong Joon Kim, Hee Joong Kang, Sung Keun Min, Ju Hyeon Yoon, Kang Sup |
author_sort | Yoon, Pil Whan |
collection | PubMed |
description | BACKGROUD: Outcomes of traditional treatment for osteonecrosis of the femoral head (ONFH) are not always satisfactory. Hence, cell-supplementation therapy has been attempted to facilitate necrotic-tissue regeneration. Adipose-derived mesenchymal stem cell (ADMSC) transplantation is potentially advantageous over bone marrow-derived MSC implantation, but its outcomes for ONFH remain unclear. The aim of this study was to determine 2-year radiological and clinical outcomes of culture-expanded autologous ADMSC implantation for ONFH. METHODS: Eighteen hips with necrotic lesions involving ≥ 30% of the femoral head were included. ADMSCs were harvested by liposuction and culture expanded for 3 passages over 3 weeks. With a 6-mm single drilling, ADMSCs were implanted into the necrotic zone. All patients underwent magnetic resonance imaging (MRI), single-photon emission computed tomography/computed tomography (SPECT/CT) at screening and 6 months, 12 months, and 24 months postoperatively. The primary outcome was the change in the size of necrotic area on MRI. Secondary outcomes were changes in clinical scores and radioisotope uptake on SPECT/CT. Conversion total hip arthroplasty (THA) was defined as the endpoint. RESULTS: Preoperatively, the necrotic lesion extent was 63.0% (38.4%–96.7%) of the femoral head. The mean Harris hip score was 89.2, the University of California at Los Angeles (UCLA) score was 5.6, and Western Ontario and McMaster Universities Arthritis index (WOMAC) was 79.4. Three patients underwent THA and 1 patient died in an accident. Finally, 11 patients (14 hips) were available for ≥ 2-year follow-up. At the last follow-up, no surgery-related complications occurred, and 14 of 17 hips (82%) were able to perform daily activities without THA requirement. There was no significant decrease in lesion size between any 2 intervals on MRI. However, widening of high signal intensity bands on T2-weighted images inside the necrotic lesion was observed in 9 of 14 hips (64%); 11 of 14 hips (79%) showed increased vascularity on SPECT/CT at 2 years postoperatively. No significant differences were observed between preoperative and 24-month mean Harris hip score (89.2 vs. 88.6), WOMAC (79.4 vs. 75.7), and UCLA score (5.6 vs. 6.2). CONCLUSIONS: Our outcomes suggest that culture-expanded ADMSC implantation is a viable option for ONFH treatment without adverse events. |
format | Online Article Text |
id | pubmed-7948035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Korean Orthopaedic Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-79480352021-03-19 Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head Yoon, Pil Whan Kang, Jong Yeal Kim, Chul-Ho Lee, Soong Joon Yoo, Jeong Joon Kim, Hee Joong Kang, Sung Keun Min, Ju Hyeon Yoon, Kang Sup Clin Orthop Surg Original Article BACKGROUD: Outcomes of traditional treatment for osteonecrosis of the femoral head (ONFH) are not always satisfactory. Hence, cell-supplementation therapy has been attempted to facilitate necrotic-tissue regeneration. Adipose-derived mesenchymal stem cell (ADMSC) transplantation is potentially advantageous over bone marrow-derived MSC implantation, but its outcomes for ONFH remain unclear. The aim of this study was to determine 2-year radiological and clinical outcomes of culture-expanded autologous ADMSC implantation for ONFH. METHODS: Eighteen hips with necrotic lesions involving ≥ 30% of the femoral head were included. ADMSCs were harvested by liposuction and culture expanded for 3 passages over 3 weeks. With a 6-mm single drilling, ADMSCs were implanted into the necrotic zone. All patients underwent magnetic resonance imaging (MRI), single-photon emission computed tomography/computed tomography (SPECT/CT) at screening and 6 months, 12 months, and 24 months postoperatively. The primary outcome was the change in the size of necrotic area on MRI. Secondary outcomes were changes in clinical scores and radioisotope uptake on SPECT/CT. Conversion total hip arthroplasty (THA) was defined as the endpoint. RESULTS: Preoperatively, the necrotic lesion extent was 63.0% (38.4%–96.7%) of the femoral head. The mean Harris hip score was 89.2, the University of California at Los Angeles (UCLA) score was 5.6, and Western Ontario and McMaster Universities Arthritis index (WOMAC) was 79.4. Three patients underwent THA and 1 patient died in an accident. Finally, 11 patients (14 hips) were available for ≥ 2-year follow-up. At the last follow-up, no surgery-related complications occurred, and 14 of 17 hips (82%) were able to perform daily activities without THA requirement. There was no significant decrease in lesion size between any 2 intervals on MRI. However, widening of high signal intensity bands on T2-weighted images inside the necrotic lesion was observed in 9 of 14 hips (64%); 11 of 14 hips (79%) showed increased vascularity on SPECT/CT at 2 years postoperatively. No significant differences were observed between preoperative and 24-month mean Harris hip score (89.2 vs. 88.6), WOMAC (79.4 vs. 75.7), and UCLA score (5.6 vs. 6.2). CONCLUSIONS: Our outcomes suggest that culture-expanded ADMSC implantation is a viable option for ONFH treatment without adverse events. The Korean Orthopaedic Association 2021-03 2020-12-21 /pmc/articles/PMC7948035/ /pubmed/33747376 http://dx.doi.org/10.4055/cios20128 Text en Copyright © 2021 by The Korean Orthopaedic Association http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Yoon, Pil Whan Kang, Jong Yeal Kim, Chul-Ho Lee, Soong Joon Yoo, Jeong Joon Kim, Hee Joong Kang, Sung Keun Min, Ju Hyeon Yoon, Kang Sup Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head |
title | Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head |
title_full | Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head |
title_fullStr | Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head |
title_full_unstemmed | Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head |
title_short | Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head |
title_sort | culture-expanded autologous adipose-derived mesenchymal stem cell treatment for osteonecrosis of the femoral head |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948035/ https://www.ncbi.nlm.nih.gov/pubmed/33747376 http://dx.doi.org/10.4055/cios20128 |
work_keys_str_mv | AT yoonpilwhan cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT kangjongyeal cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT kimchulho cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT leesoongjoon cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT yoojeongjoon cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT kimheejoong cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT kangsungkeun cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT minjuhyeon cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead AT yoonkangsup cultureexpandedautologousadiposederivedmesenchymalstemcelltreatmentforosteonecrosisofthefemoralhead |